Gene therapy for lung cancer

被引:21
作者
Dubinett, SM
Miller, PW
Sharma, S
Batra, RK
机构
[1] Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Wadsworth Pulm Immunol Lab, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Sch Med, Los Angeles, CA 90024 USA
关键词
D O I
10.1016/S0889-8588(05)70009-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the major cause of cancer-realted mortality, accounting for approximately 30% of all such deaths in the United States every year. Although few patients have been treated, the preliminary results of the phase I lung cancer gene therapy clinical trials are promising. Clinically relevant basic research in the molecular pathogenesis and immunology of lung cancer is progressing. As improved vector technologies are developed, new opportunities will be available to initiate lung cancer gene therapy trials based on a more detailed understanding of lung cancer biology. Although important biological and technical questions remain unanswered, recent research suggests that gene therapy will have a profound impact on lung cancer treatment.
引用
收藏
页码:569 / +
页数:28
相关论文
共 241 条
[51]   CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION [J].
DAI, YF ;
SCHWARZ, EM ;
GU, DL ;
ZHANG, WW ;
SARVETNICK, N ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1401-1405
[52]   INTERLEUKIN-10 (IL-10) INHIBITS HUMAN LYMPHOCYTE INTERFERON GAMMA-PRODUCTION BY SUPPRESSING NATURAL-KILLER-CELL STIMULATORY FACTOR/IL-12 SYNTHESIS IN ACCESSORY CELLS [J].
DANDREA, A ;
ASTEAMEZAGA, M ;
VALIANTE, NM ;
MA, XJ ;
KUBIN, M ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1041-1048
[53]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398
[54]  
DECLERCK YA, 1992, CANCER RES, V52, P701
[55]   Targeted tumor killing via an intracellular antibody against erbB-2 [J].
Deshane, J ;
Siegal, GP ;
Alvarez, RD ;
Wang, MH ;
Feng, MZ ;
Cabrera, G ;
Liu, TP ;
Kay, M ;
Curiel, DT .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2980-2989
[56]   Combined chemokine and cytokine gene transfer enhances antitumor immunity [J].
Dilloo, D ;
Bacon, K ;
Holden, W ;
Zhong, WY ;
Burdach, S ;
Zlotnik, A ;
Brenner, M .
NATURE MEDICINE, 1996, 2 (10) :1090-1095
[57]   Adjuvant therapy for stage I and II non-small cell lung cancer [J].
Dorr, VJ ;
Perry, MC .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (02) :267-+
[58]  
DOUGHERTY GJ, 1994, CANCER IMMUNOL IMMUN, V38, P339, DOI 10.1007/s002620050075
[59]   Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors [J].
Douglas, JT ;
Curiel, DT .
NEUROMUSCULAR DISORDERS, 1997, 7 (05) :284-298
[60]   Targeted gene delivery by tropism-modified adenoviral vectors [J].
Douglas, JT ;
Rogers, BE ;
Rosenfeld, ME ;
Michael, SI ;
Feng, MZ ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 1996, 14 (11) :1574-1578